Business Context and Reporting Period
Company: Marathon Patent Group, Inc. (Note: Request metadata referenced "MARA Holdings, Inc.", but the filing text identifies the registrant as Marathon Patent Group, Inc.)
Reporting Date: October 10, 2014
Event: The Company entered into an Interest Sale Agreement to acquire 100% of the membership interests of OrthoPhoenix, LLC and TLIF, LLC, and 100% of the shares of MedTech Development Deutschland GmbH from MedTech Development, LLC. These subsidiaries hold medical technology patents, pending litigation, and licensing rights.
Key Financial Metrics and Obligations
This filing details a transaction structure rather than standard operating financial metrics (revenue, profit, cash flow). Key financial obligations include:
- Upfront Payment: $1 million payable at closing.
- Deferred Payments: $1 million payable on each of the next nine monthly anniversaries of closing (Total: $9 million).
- Promissory Note: A $9 million principal note issued to MedTech, maturing in July 2015.
- Participation Payments: Additional payments to MedTech from recoveries after the Subsidiaries receive 200% of the Purchase Payments plus out-of-pocket expenses. These may be paid in Marathon common stock.
- Interest Rate: The Note is non-interest bearing unless an event of default occurs, at which point interest accrues at the lower of 22% per annum or the maximum rate allowed by Texas law.
Material Changes and Transaction Terms
The primary material change is the acquisition of patent assets and litigation rights. The transaction includes specific prepayment triggers for the $9 million Note:
- Financing Trigger: If the Company raises $15 million or more in debt or equity financing prior to full payment, the Note must be prepaid within two business days.
- Revenue Trigger: The Note requires prepayment from net proceeds generated by licensing fees and patent claim recoveries.
- Related Party: Approximately 45% of MedTech is owned or controlled by Erich Spangenberg or his family/associates.
Guidance, Risks, and Contingencies
Contingencies: Future cash outflows are contingent upon the success of patent litigation and licensing efforts by the acquired subsidiaries. The Company has the option to satisfy participation payments via common stock issuance, subject to lockup and registration rights agreements.
Risks: The Note carries a significant penalty interest rate (up to 22%) upon default. The Company faces liquidity pressure if it raises significant capital or generates patent recoveries, as these events trigger mandatory prepayment of the $9 million debt.
Financial Statements: Audited financial statements for the acquired subsidiaries for fiscal years 2012 and 2013, and unaudited statements for the quarters ended September 30, 2013 and 2014, are to be filed as exhibits. Pro forma financial information is also pending as an exhibit.
Investor Verification Checklist
- Verify the total cash outflow commitment ($10 million in scheduled payments plus potential participation payments).
- Confirm the status of the pending litigation and patent claims held by OrthoPhoenix, TLIF, and MedTech GmbH.
- Review the upcoming exhibits (99.1, 99.2, 99.3) for the acquired subsidiaries' historical financial performance and pro forma impact.
- Assess the Company's current liquidity to meet the $1 million closing payment and subsequent monthly obligations.
- Monitor for any future financing rounds exceeding $15 million, which would trigger immediate repayment of the $9 million note.